Edwards Lifesciences Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss increased by 14.3% to $1.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 59.0%, from $3.90M to $1.60M. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss shows a downward trend with a -41.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates a decline in the overall market value of the investment portfolio relative to its cost basis.
The total accumulated unrealized losses across all available-for-sale debt securities, regardless of the duration of the...
A standard balance sheet metric for financial institutions reflecting total unrealized loss exposure.
other_debt_securities_available_for_sale_unrealized_loss_2eb75f| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.20M | $2.10M | $11.90M | $52.00M | $67.60M | $78.00M | $68.10M | $55.10M | $49.20M | $38.70M | $27.50M | $18.00M | $12.80M | $6.90M | $5.30M | $3.90M | $2.80M | $2.00M | $1.40M | $1.60M |
| QoQ Change | — | +75.0% | +466.7% | +337.0% | +30.0% | +15.4% | -12.7% | -19.1% | -10.7% | -21.3% | -28.9% | -34.5% | -28.9% | -46.1% | -23.2% | -26.4% | -28.2% | -28.6% | -30.0% | +14.3% |
| YoY Change | — | — | — | — | >999% | >999% | +472.3% | +6.0% | -27.2% | -50.4% | -59.6% | -67.3% | -74.0% | -82.2% | -80.7% | -78.3% | -78.1% | -71.0% | -73.6% | -59.0% |